• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

    4/29/26 5:30:47 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JANX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Janux Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    47103J105

    (CUSIP Number)
    04/28/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    47103J105


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,069,759.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,069,759.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,069,759.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    47103J105


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,069,759.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,069,759.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,069,759.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    47103J105


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,069,759.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,069,759.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,069,759.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Janux Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    10955 Vista Sorrento Parkway, Suite 200, San Diego, California 92130
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Janux Therapeutics, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited, Point72 Asia (Singapore) Pte. Ltd. and Point72 Europe (London) LLP are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the shares of Common Stock reported herein. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP Number(s):

    47103J105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 28, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
    (b)Percent of class:

    5.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 28, 2026.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 28, 2026.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 28, 2026.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 28, 2026.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:04/29/2026
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:04/29/2026
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:04/29/2026
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $JANX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JANX

    DatePrice TargetRatingAnalyst
    4/20/2026$14.00Overweight → Underweight
    Barclays
    4/15/2026$15.00Buy → Neutral
    UBS
    11/18/2025Peer Perform
    Wolfe Research
    9/17/2025$47.00Overweight
    Barclays
    9/10/2025$45.00Buy
    Stifel
    9/10/2025$100.00Buy
    Truist
    9/4/2025$72.00Buy
    Guggenheim
    8/19/2025$42.00Overweight
    Piper Sandler
    More analyst ratings

    $JANX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

    SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    5/15/26 12:38:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

    SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

    5/12/26 11:18:42 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Janux Therapeutics Inc.

    10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)

    5/7/26 4:33:47 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel sold $56,944 worth of shares (4,059 units at $14.03), decreasing direct ownership by 5% to 75,941 units (SEC Form 4) to satisfy tax liability

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    6/4/26 8:00:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vice President, Accounting Dobek Maria sold $28,878 worth of shares (2,038 units at $14.17), decreasing direct ownership by 6% to 32,270 units (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    5/13/26 8:00:09 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Go William was granted 44,000 shares (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    2/4/26 8:01:40 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Janux Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Janux Therapeutics from Overweight to Underweight and set a new price target of $14.00

    4/20/26 8:24:09 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics downgraded by UBS with a new price target

    UBS downgraded Janux Therapeutics from Buy to Neutral and set a new price target of $15.00

    4/15/26 8:07:01 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Janux Therapeutics

    Wolfe Research initiated coverage of Janux Therapeutics with a rating of Peer Perform

    11/18/25 8:24:27 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

    JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results fo

    5/7/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

    Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal review of the data, the Company has determined to prioritize development resources toward other pipeline opportunities. The decision to discontinue JANX008 is program-specific and does not impact the Company's broader TRACTr platfor

    4/27/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

    -JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio -JANX007 is the Company's lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tu

    4/16/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    3/7/25 6:05:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    10/22/24 4:20:04 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    11/15/23 4:48:17 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Leadership Updates

    Live Leadership Updates

    View All

    Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

    JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results fo

    5/7/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma

    2/26/26 4:01:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

    Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i

    1/26/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:24:38 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:17:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:01:49 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Financials

    Live finance-specific insights

    View All

    Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

    Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

    7/17/23 8:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care